H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on BRNS stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen has given his Buy rating due to a combination of factors surrounding Barinthus Biotherapeutics’ ongoing clinical developments and financial outlook. The company is making significant progress with its VTP-1000 program, which is currently in the Phase 1 AVALON trial for celiac disease. The trial’s single ascending dose (SAD) portion has shown promising safety results with no serious adverse events reported, and data from this portion is expected in early 4Q25. Additionally, the initiation of the multiple ascending dose (MAD) portion of the trial, which includes a controlled gluten challenge, further supports the potential efficacy of VTP-1000.
Financially, Barinthus Biotherapeutics is well-positioned with a cash runway extending into 2027, providing a solid foundation for continued research and development. The company’s strategic focus on advancing its pipeline, including seeking partnerships for its VTP-300 and VTP-850 programs, indicates a proactive approach to growth and innovation. Despite the competitive landscape with other companies like Sanofi and Teva developing treatments for celiac disease, Barinthus’s unique approach with VTP-1000 positions it favorably in the market. These factors collectively underpin Yi Chen’s Buy rating and the $3 price target for the stock.
According to TipRanks, Chen is an analyst with an average return of -8.2% and a 36.38% success rate. Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, EyePoint Pharmaceuticals, and Lipocine.